Triflusal

HCID 9458CAS 322-79-2

Basic information

Standard SMILES
CC(=O)Oc1cc(C(F)(F)F)ccc1C(=O)O
InChIKey
RMWVZGDJPAKBDE-UHFFFAOYSA-N
Molecular formula
C10H7F3O4
Average molar mass
248.15 g/mol
Monoisotopic mass
248.02964319

Names & identifiers

Preferred name
Triflusal
IUPAC
2-acetyloxy-4-(trifluoromethyl)benzoic acid
English name
Triflusal
Molecular formula
C10H7F3O4
Molecular weight
248.16

Names & synonyms

Triflusal322-79-22-Acetoxy-4-trifluoromethylbenzoic acid2-(Acetyloxy)-4-(trifluoromethyl)benzoic acidTriflusalumDTXSID80453051Z0YFI05OODTXCID6025305RefChem:191611B01AC18206-297-5Disgren
Show more names
ur1501DrisgenTriflusal-d3Triflusal CRSTriflusal (UR1501)TRIFLUOROTRIMESICACIDTriflusal, 10 mM in DMSO4-trifluoromethylsalicylicacidacetate
2-Acetoxy-4-(trifluoromethyl)benzoic Acid2-acetyloxy-4-(trifluoromethyl)benzoic acidTriflusal [INN]C10H7F3O4MFCD00866793Benzoic acid, 2-(acetyloxy)-4-(trifluoromethyl)-alpha,alpha,alpha-Trifluoro-2,4-cresotic acid acetateTriflusal (INN)

Database identifiers

CAS
322-79-2
PubChem CID
9458
DTXSID
DTXSID8045305
ChEMBL
CHEMBL1332032
ChEBI
CHEBI:94721
UNII
1Z0YFI05OO
EC Number
206-297-5
Nikkaji
J5.672C

Properties

Computed structural properties

XLogP
2.1
Topological polar surface area
63.6 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
7
Rotatable bonds
3
Heavy atoms
17

Physicochemical properties

Melting point
120 · 120-122° (upon slow heating); 110-112° (upon quick heating)
Boiling point
316 · 316.0±42.0 °C(Predicted)
Density
1.433 · 1.433±0.06 g/cm3(Predicted)
storage temp.
2 · Sealed in dry,2-8°C
solubility
30 mg/mL · DMSO: >30mg/mL
pka
2.97 · 2.97±0.10(Predicted)

Safety & regulation

Safety data

wgk
3
rtecs
GP4250000
hs_code
2918.29.7500
risk_code
22-36/37/38-43
Signal word
Warning
Symbol(GHS)
GHS07

Chemistry & industry

Applications · 3 items

DescriptionTriflusal is an antiplatelet agent structurally related to the salicylates, but it is not derived from ASA. Triflusal and its metabolite (3-hydroxy-4-triuoro-methylbenzoic acid or HTB) produce specic inhibition of platelet arachidonic acid metabolism (McNeely and Goa, 1998). A single 12-month open-label trial of Triflusal in 73 VaD patients (López-Pousa et al., 1997) showed fewer declines in MMSE scores in the active group compared with untreated subjects. More recently, Triflusal was used in patients with amnesic MCI; 257 patients were randomized to receive 900 mg of Triflusal or placebo for 18 months. Triflusal therapy was associated with a signicantly lower rate of conversion to dementia (Gómez-Isla et al., 2008).

UsesAn analog of Aspirin; inhibits platelet aggregation. Antithrombotic.

UsesAntithrombotic;Cyclooxygenase inhibitor

Upstream & downstream products

Suppliers50 total

上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
Shandong chuangyingchemical Co., Ltd.18853181302 · [email protected]
南通飞宇生物科技有限公司0513-68819626 15152877458 · [email protected]
武汉英诺医药科技有限公司+86-027-59232304 15387063101 · [email protected]
艾吉析科技(上海)有限公司17717235263 · [email protected]

Additional notes

DefinitionChEBI: 2-acetyloxy-4-(trifluoromethyl)benzoic acid is a member of salicylates, a carboxylic ester and a member of benzoic acids.

Related reactions

2 records

Linked notes

Loading…